all report title image
  • Published On : Aug 2022
  • Code : CMI1698
  • Industry : Biotechnology
  • Pages : 192
  • Formats :

Cryopreservation is a process of maintaining biological samples in the form of a suspended state at cryogenic temperature for a considerable period and is used to preserve the fine structure of cells. Through this process, samples of cells, tissues, and organelles are cooled at very low temperatures (less than - 2130 degrees F) for preservation. Cryopreservation is primarily used in the preservation of oocytes and embryos during the in-vitro fertilization (IVF) cycle, prior to chemotherapy for women diagnosed with breast cancer, in order to preserve their reproductive capacity.

The global cell cryopreservation market size was valued at US$ 8,659.4 Million in 2022 and is expected to witness a CAGR of 22.4% over the forecast period (2022 – 2030).

Figure 1. Global Cell Cryopreservation Share (%), by Application, 2022

Cell Cryopreservation  | Coherent Market Insights

Increasing research and development of stem cells is expected to augment the growth of the global cell cryopreservation over the forecast period.

Increasing research and development of stem cells by scientists and clinicians is expected to boost the global cell cryopreservation market growth. For instance, in November 2021, the University of Southern California received a US$5 million grant from the California Institute for Regenerative Medicine to help PhD students, clinical research fellows, and postdoctoral researchers advance their careers in stem cell research. A varied group of scientists with unmatched expertise and abilities will emerge from the training program as the next generation of leaders in stem cell research.

CMI table icon

Cell Cryopreservation Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 8,659.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 22.4% 2030 Value Projection: US$ 43,546.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Cryoprotectant Agents (Glycerol, Dimethyl Sulfoxide (DMSO), Others), Equipment (Incubators, Liquid Nitrogen Supply Tanks, Freezers, Others)
  • By Application: Stem Cells, Oocytes and Embryos, Sperm, Semen, and Testicular Tissue, Hepatocytes, Others
  • By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Biobank, Others
Companies covered:

General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, AMS Biotechnology (Europe) Limited, Miltenyi Biotec GmbH, BioLife Solutions Inc., HiMedia Laboratories Pvt. Ltd., PromoCell GmbH, Corning Incorporated, Cooper Companies, Inc., Planer PLC, Bio-Rad Laboratories India Pvt. Ltd, Abcam plc., AMSBIO, Biogenuix, and Evia Bio.

Growth Drivers:
  • Increasing research and development of stem cells
  • Increasing demand for in vitro fertilization (IVF) procedures
Restraints & Challenges:
  • The adoption and development of alternative methods

Figure 2. Global Cell Cryopreservation Market Share (%), by Region, 2022

Cell Cryopreservation  | Coherent Market Insights

Increasing demand for in vitro fertilization (IVF) procedures in North America is expected to boost the market growth

North America holds a dominant position in the global cell cryopreservation market, owing to increasing demand for in vitro fertilization (IVF) procedures in the U.S. For instance, in 2021, according to the report published by Cofertility, a fertility treatment center, 1.9% of babies were born by IVF in the U.S. in 2018. 2 out of 3 women who start IVF before age 35 will take home a baby within three IVF cycles.

Moreover, according to the Centers for Disease Control and Prevention, a national public health agency, in 2018, about 1% to 2% of all births in the U.S. annually are through IVF procedures which shows the significant usage of cryopreservation equipment.

Global Cell Cryopreservation Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020. The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with an increased burden on hospitals and healthcare professionals. Increasing launch during covid-19 by the market players has driven the global cell cryopreservation market growth. For instance, in March 2021, Helmer Scientific, a manufacturer of cold storage products and processing equipment, announced the expansion of the GX Solutions’, a monitoring company, Cold Storage product line to include both undercounter and upright freezers. GX Solutions Freezers include models that are designed for vaccine and blood therapies, as well as other clinical applications in capacity range from 5 to 25 cu ft. GX Solutions are medical-grade freezers that are powered by OptiCool technology and optimize temperature, noise, and energy management. Medical-grade freezers are required for a wide variety of healthcare applications. However, this equipment category has recently become even more critical as healthcare providers need to meet storage and handling requirements of new COVID-19 vaccines.

Global Cell Cryopreservation Market: Key Developments

  • In May 2022, Bristol Myers Squibb, a global biopharmaceutical company, announced that the European Commission (EC) had granted Marketing Authorization for Breyanzi, a CD19(B-lymphocyte antigen)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more lines of systemic therapy. The Marketing Authorization approved Breyanzi for use in all European Union (EU) member states.
  • In July 2020, Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to Tecartus, the approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval of this one-time therapy follows a priority review and FDA Breakthrough Therapy Designation and is based on the results of ZUMA-2, a single-arm, open-label study in which 87% of patients responded to a single infusion of Tecartus, including 18% who experienced Grade 3 or higher cytokine release syndrome (CRS) and 62% of patients achieving a complete response (CR). Among patients evaluable for safety, 37% experienced Grade 3 or higher neurologic toxicities.

Global Cell Cryopreservation Market Restraints

The adoption and development of alternative methods is expected to hinder the market growth. For instance, in May 2019, researchers at the University of Japan developed a technique to cryopreserve animal cells without using a cryoprotectant agent. The researchers plan to apply this technique to a wide range of cells, especially cells sensitive to the cryopreservation procedure.

 Key Players

Key players operating in the global cell cryopreservation market include General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, AMS Biotechnology (Europe) Limited, Miltenyi Biotec GmbH, BioLife Solutions Inc., HiMedia Laboratories Pvt. Ltd., PromoCell GmbH, Corning Incorporated, Cooper Companies, Inc., Planer PLC, Bio-Rad Laboratories India Pvt. Ltd, Abcam plc., AMSBIO, Biogenuix, and Evia Bio.

The process of stabilizing biological materials at cryogenic temperatures (below -1500 degree C) is called cryopreservation. Cryopreservation is used for the preservation of microorganisms, tissue cells, established cell lines, small multicellular organisms, and complex cellular structures such as embryos, nucleic acid, and proteins. Cryopreservation procedures use liquid nitrogen, liquid helium, argon, and oxygen as cryogenic elements. Various types of samples with varying sensitivity require different types of cryopreservation equipment such as cryopreservation freezers, liquid nitrogen vessels, cryogenic vaporizers, cryogenic incubators, liquid tracking equipment, and cell freezing container.

Market Dynamics

Increasing product launches by market players in cell therapy is a major factor driving the global cell cryopreservation market growth. For instance, in April 2021, BioLife Solutions, Inc., a developer and supplier of bioproduction products and services for cell and gene therapies, announced that it had launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to cell therapy. The freezer will be a critical component in the management of several allogeneic cell therapies in development. This product launch expands the company cryogenic freezer platform with high-capacity controlled rate freezers designed specifically to meet the needs of cell and gene therapy developers. 

Furthermore, a decrease in the fertility rate is expected to drive the market growth. For instance on July 17, 2022, the World Economic forum, an international non-governmental and lobbying organization, published a report which stated that fertility rates have decreased worldwide, with a total 50% decline over the last 70 years.

Key features of the study:

  • This report provides in-depth analysis of the global cell cryopreservation market, market size (US$ Million), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global cell cryopreservation market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, AMS Biotechnology (Europe) Limited, Miltenyi Biotec GmbH, BioLife Solutions , HiMedia Laboratories Pvt. Ltd., PromoCell GmbH, Corning Incorporated, Cooper Companies, Inc., Planer PLC, Bio-Rad Laboratories India Pvt. Ltd, Abcam plc., AMSBIO, Biogenuix, and Evia Bio.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global cell cryopreservation market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global cell cryopreservation market.

Detailed Segmentation:

  • Global Cell Cryopreservation Market, By Product Type:
    • Cryoprotectant Agents
      • Glycerol
      • Dimethyl Sulfoxide (DMSO)
      • Others
    • Equipment
      • Incubators
      • Liquid Nitrogen Supply Tanks
      • Freezers
      • Others
  •  Global Cell Cryopreservation Market, By Application:
    • Stem Cells
    • Oocytes and Embryos
    • Sperm, Semen, and Testicular Tissue
    • Hepatocytes
    • Others
  •  Global Cell Cryopreservation Market, By End User:
    • Pharmaceutical and Biotechnology Companies
    • Academic and Research Institutes
    • Biobank
    • Others
  •  Global Cell Cryopreservation Market, By Region:
    • North America
      • By Country
        • US
        • Canada
    • Europe
      • By Country
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region 
        • South Africa
        • Central Africa
        • North Africa
  • By Company Profiles
    • General Electric Company.*
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • AMS Biotechnology (Europe) Limited
    • Miltenyi Biotec GmbH
    • BioLifeSolutions
    • HiMedia Laboratories Pvt. Ltd.
    • PromoCell GmbH
    • Corning Incorporated
    • Cooper Companies, Inc.
    • Planer PLC
    • Bio-Rad Laboratories India Pvt. Ltd
    • Abcam plc.
    • AMSBIO
    • Biogenuix

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global cell cryopreservation market is estimated to surpass US$ 43,546.4 Million by 2030.
Major players operating in the market include General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, AMS Biotechnology (Europe) Limited, Miltenyi Biotec GmbH, BioLife Solutions Inc., HiMedia Laboratories Pvt. Ltd., PromoCell GmbH, Corning Incorporated, Cooper Companies, Inc., Planer PLC, Bio-Rad Laboratories India Pvt. Ltd, Abcam plc., AMSBIO, Biogenuix, and Evia Bio.
Among applications, the stem cells segment has generated significant revenue in 2022, owing to increasing research and development of stem cells.
Increasing demand for in vitro fertilization (IVF) procedures is one of the major factors that is expected to propel the market growth over the forecast period.
The market is estimated to exhibit a CAGR of 22.4% over the forecast period.
Among regions, North America is expected to witness significant growth over the forecast period, owing to increasing demand for in vitro fertilization (IVF) procedures in the U.S.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo